1.Korean Practice Guidelines for Gastric Cancer 2022: An Evidence-based, Multidisciplinary Approach
Tae-Han KIM ; In-Ho KIM ; Seung Joo KANG ; Miyoung CHOI ; Baek-Hui KIM ; Bang Wool EOM ; Bum Jun KIM ; Byung-Hoon MIN ; Chang In CHOI ; Cheol Min SHIN ; Chung Hyun TAE ; Chung sik GONG ; Dong Jin KIM ; Arthur Eung-Hyuck CHO ; Eun Jeong GONG ; Geum Jong SONG ; Hyeon-Su IM ; Hye Seong AHN ; Hyun LIM ; Hyung-Don KIM ; Jae-Joon KIM ; Jeong Il YU ; Jeong Won LEE ; Ji Yeon PARK ; Jwa Hoon KIM ; Kyoung Doo SONG ; Minkyu JUNG ; Mi Ran JUNG ; Sang-Yong SON ; Shin-Hoo PARK ; Soo Jin KIM ; Sung Hak LEE ; Tae-Yong KIM ; Woo Kyun BAE ; Woong Sub KOOM ; Yeseob JEE ; Yoo Min KIM ; Yoonjin KWAK ; Young Suk PARK ; Hye Sook HAN ; Su Youn NAM ; Seong-Ho KONG ;
Journal of Gastric Cancer 2023;23(1):3-106
Gastric cancer is one of the most common cancers in Korea and the world. Since 2004, this is the 4th gastric cancer guideline published in Korea which is the revised version of previous evidence-based approach in 2018. Current guideline is a collaborative work of the interdisciplinary working group including experts in the field of gastric surgery, gastroenterology, endoscopy, medical oncology, abdominal radiology, pathology, nuclear medicine, radiation oncology and guideline development methodology. Total of 33 key questions were updated or proposed after a collaborative review by the working group and 40 statements were developed according to the systematic review using the MEDLINE, Embase, Cochrane Library and KoreaMed database. The level of evidence and the grading of recommendations were categorized according to the Grading of Recommendations, Assessment, Development and Evaluation proposition. Evidence level, benefit, harm, and clinical applicability was considered as the significant factors for recommendation. The working group reviewed recommendations and discussed for consensus. In the earlier part, general consideration discusses screening, diagnosis and staging of endoscopy, pathology, radiology, and nuclear medicine. Flowchart is depicted with statements which is supported by meta-analysis and references. Since clinical trial and systematic review was not suitable for postoperative oncologic and nutritional follow-up, working group agreed to conduct a nationwide survey investigating the clinical practice of all tertiary or general hospitals in Korea. The purpose of this survey was to provide baseline information on follow up. Herein we present a multidisciplinary-evidence based gastric cancer guideline.
2.Effects of Particulate Matter Exposure on the Eustachian Tube and Middle Ear Mucosa of Rats
Hyun Min LEE ; Youn-Suk SON ; Hyang-Sook KIM ; Joo-Young KIM ; Seok-Hyun KIM ; Jung Hee LEE ; Sung-Won CHOI ; Se-Joon OH ; Soo-Keun KONG ; Moo Jin BAEK ; Il-Woo LEE
Clinical and Experimental Otorhinolaryngology 2023;16(3):225-235
Objectives:
. Particulate matter (PM) is a risk factor for various diseases. Recent studies have established an association between otitis media (OM) and PM exposure. To confirm this relationship, we developed a novel exposure model designed to control the concentration of PM, and we observed the effects of PM exposure on the Eustachian tube (ET) and middle ear mucosa of rats.
Methods:
. Forty healthy, 10-week-old, male Sprague-Dawley rats were divided into 3-day, 7-day, 14-day exposure, and control groups (each, n=10). The rats were exposed to incense smoke as the PM source for 3 hours per day. After exposure, bilateral ETs and mastoid bullae were harvested, and histopathological findings were compared using microscopy and transmission electron microscopy (TEM). The expression levels of interleukin (IL)-1β, IL-6, tumor necrosis factor-α, and vascular endothelial growth factor (VEGF) in the middle ear mucosa of each group were compared using real-time reverse transcription polymerase chain reaction (RT-PCR).
Results:
. In the ET mucosa of the exposure group, the goblet cell count significantly increased after PM exposure (P=0.032). In the middle ear mucosa, subepithelial space thickening, increased angio-capillary tissue, and inflammatory cell infiltration were observed. Moreover, the thickness of the middle ear mucosa in the exposure groups increased compared to the control group (P<0.01). The TEM findings showed PM particles on the surface of the ET and middle ear mucosa, and RT-PCR revealed that messenger RNA (mRNA) expression of IL-1β significantly increased in the 3-day and 7-day exposure groups compared to the control group (P=0.035). VEGF expression significantly increased in the 7-day exposure group compared to the control and 3-day exposure groups (P<0.01).
Conclusion
. The ET and middle ear mucosa of rats showed histopathologic changes after acute exposure to PM that directly reached the ET and middle ear mucosa. Therefore, acute exposure to PM may play a role in the development of OM.
3.Erratum: Korean Practice Guidelines for Gastric Cancer 2022: An Evidencebased, Multidisciplinary Approach
Tae-Han KIM ; In-Ho KIM ; Seung Joo KANG ; Miyoung CHOI ; Baek-Hui KIM ; Bang Wool EOM ; Bum Jun KIM ; Byung-Hoon MIN ; Chang In CHOI ; Cheol Min SHIN ; Chung Hyun TAE ; Chung sik GONG ; Dong Jin KIM ; Arthur Eung-Hyuck CHO ; Eun Jeong GONG ; Geum Jong SONG ; Hyeon-Su IM ; Hye Seong AHN ; Hyun LIM ; Hyung-Don KIM ; Jae-Joon KIM ; Jeong Il YU ; Jeong Won LEE ; Ji Yeon PARK ; Jwa Hoon KIM ; Kyoung Doo SONG ; Minkyu JUNG ; Mi Ran JUNG ; Sang-Yong SON ; Shin-Hoo PARK ; Soo Jin KIM ; Sung Hak LEE ; Tae-Yong KIM ; Woo Kyun BAE ; Woong Sub KOOM ; Yeseob JEE ; Yoo Min KIM ; Yoonjin KWAK ; Young Suk PARK ; Hye Sook HAN ; Su Youn NAM ; Seong-Ho KONG
Journal of Gastric Cancer 2023;23(2):365-373
4.Prediction of Cancer Incidence and Mortality in Korea, 2020
Kyu-Won JUNG ; Young-Joo WON ; Seri HONG ; Hyun-Joo KONG ; Eun Sook LEE
Cancer Research and Treatment 2020;52(2):351-358
Purpose:
This study aimed to report the projected cancer incidence and mortality for the year 2020to estimate Korea’s current cancer burden.
Materials and Methods:
Cancer incidence data from 1999 to 2017 were obtained from the Korea National CancerIncidence Database, and cancer mortality data from 1993 to 2018 were acquired from StatisticsKorea. Cancer incidence and mortality were projected by fitting a linear regressionmodel to observed age-specific cancer rates against observed years and then by multiplyingthe projected age-specific rates by the age-specific population. A Joinpoint regression modelwas used to determine the year in which the linear trend changed significantly; we only usedthe data of the latest trend.
Results:
In total, 243,263 new cancer cases and 80,546 cancer deaths are expected to occur inKorea in 2020. The most common cancer site is expected to be the lung, followed by thestomach, thyroid, colon/rectum, and breast. These five cancers types are expected to representhalf of the overall burden of cancer in Korea. The most common type of canceramong people who die is expected to be lung cancer, followed by liver, colon/rectal, pancreatic,and stomach cancers.
Conclusion
The incidence rates for all types of cancer in Korea are estimated to decrease gradually.These up-to-date estimates of the cancer burden in Korea could be an important resourcefor planning and evaluating cancer-control programs.
5.Outcomes of Pregnancy after Breast Cancer in Korean Women:A Large Cohort Study
Moo Hyun LEE ; Young Ae KIM ; Jin Hyuk HONG ; So-Youn JUNG ; Sunmi LEE ; Sun-Young KONG ; Boyoung PARK ; Eun Sook LEE
Cancer Research and Treatment 2020;52(2):426-437
Purpose:
The purpose of this study was to determine the rate and outcomes of pregnancies subsequentto breast cancer in Korea, and the effect of such pregnancies on the prognosis ofwomen who survived breast cancer and subsequently conceived.
Materials and Methods:
We followed a total of 31,761 Korean women 45 years of age or younger who were treatedfor primary breast cancer from 2002 to 2010. We also included follow-up surveys that wereconducted through December 2011. We identified recurrence and mortality from breastcancer using data linked to the Korea National Health Insurance database. We used propensityscore matching of the study cohort to analyze the risks of recurrence and mortality frombreast cancer depending on pregnancy.
Results:
Within our sample, 992 women (3.1%) became pregnant after receiving treatment for breastcancer. Of those, 622 (67.5%) successfully delivered; the remaining 370 (32.5%) failed todeliver. After propensity score matching, we found that the women who became pregnantafter breast cancer did not have a different risk of recurrence (hazard ratio [HR], 0.503;95% confidence interval [CI], 0.434 to 0.584) and death (HR, 0.520; 95% CI, 0.397 to0.681), compared with those who did not conceive after breast cancer treatment.
Conclusion
Our study is the first to report outcomes for Korean women who survived breast cancer andsubsequently conceived. Women who survived breast cancer and subsequently becamepregnant did not show a poorer survival outcome, compared with those who did not becomepregnant.
6.Cancer Statistics in Korea: Incidence, Mortality, Survival, andPrevalence in 2017
Seri HONG ; Young-Joo WON ; Young Ran PARK ; Kyu-Won JUNG ; Hyun-Joo KONG ; Eun Sook LEE ; ;
Cancer Research and Treatment 2020;52(2):335-350
Purpose:
This study reports the cancer statistics and temporal trends in Korea on a nationwide scale,including incidence, survival, prevalence, and mortality in 2017.
Materials and Methods:
The incidence, survival, and prevalence rates of cancer were evaluated using data from theKorea National Cancer Incidence Database from 1999 to 2017 with follow-up until December31, 2018. Deaths from cancer were assessed using cause-of-death data from 1983 to2017, obtained from Statistics Korea. Crude and age-standardized rates (ASRs) for incidence,mortality, and prevalence, and 5-year relative survival rates were calculated andtrend analysis was performed.
Results:
In 2017, newly diagnosed cancer cases and deaths from cancer numbered 232,255 (ASR,264.4 per 100,000) and 78,863 (ASR, 76.6 per 100,000), respectively. The overall cancerincidence rates increased annually by 3.5% from 1999 to 2011 and decreased by 2.7%annually thereafter. Cancer mortality rates have been decreasing since 2002, by 2.8%annually. The 5-year relative survival rate for all patients diagnosed with cancer between2013 and 2017 was 70.4%, which contributed to a prevalence of approximately 1.87 millioncases by the end of 2017.
Conclusion
The burden of cancer measured by incidence and mortality rates have improved in Korea,with the exception of a few particular cancers that are associated with increasing incidenceor mortality rates. However, cancer prevalence is increasing rapidly, with the dramaticimprovement in survival during the past several years. Comprehensive cancer control strategiesand efforts should continue, based on the changes of cancer statistics.
7.Asian Society of Gynecologic Oncology International Workshop 2018
Tae Wook KONG ; Hee Sug RYU ; Seung Cheol KIM ; Takayuki ENOMOTO ; Jin LI ; Kenneth H KIM ; Seung Hyuk SHIM ; Peng Hui WANG ; Suwanit THERASAKVICHYA ; Yusuke KOBAYASHI ; Maria LEE ; Tingyan SHI ; Shin Wha LEE ; Mikio MIKAMI ; Satoru NAGASE ; Myong Cheol LIM ; Jianliu WANG ; Sarikapan WILAILAK ; Sang Wun KIM ; Sook Hee HONG ; David SP TAN ; Masaki MANDAI ; Suk Joon CHANG ; Ruby Yun Ju HUANG ; Kimio USHIJIMA ; Jung Yun LEE ; Xiaojun CHEN ; Kazunori OCHIAI ; Taek Sang LEE ; Bingyi YANG ; Farhana KALAM ; Qiaoying LV ; Mohd Faizal AHMAD ; Muhammad Rizki YAZNIL ; Kanika Batra MODI ; Manatsawee MANOPUNYA ; Dae Hoon JEONG ; Arb aroon LERTKHACHONSUK ; Hyun Hoon CHUNG ; Hidemichi WATARI ; Seob JEON
Journal of Gynecologic Oncology 2019;30(2):e39-
The Asian Society of Gynecologic Oncology International Workshop 2018 on gynecologic oncology was held in the Ajou University Hospital, Suwon, Korea on the 24th to 25th August 2018. The workshop was an opportunity for Asian doctors to discuss the latest findings of gynecologic cancer, including cervical, ovarian, and endometrial cancers, as well as the future of fertility-sparing treatments, minimally invasive/radical/debulking surgery, radiotherapy, chemotherapy, targeted therapy, and immunotherapy. Clinical guidelines and position statement of Asian countries were presented by experts. Asian clinical trials for gynecologic cancers were reviewed and experts emphasized the point that original Asian study is beneficial for Asian patients. In Junior session, young gynecologic oncologists presented their latest research on gynecologic cancers.
Antineoplastic Agents
;
Asian Continental Ancestry Group
;
Drug Therapy
;
Education
;
Endometrial Neoplasms
;
Female
;
Gyeonggi-do
;
Humans
;
Immunotherapy
;
Korea
;
Ovarian Neoplasms
;
Radiotherapy
;
Uterine Cervical Neoplasms
8.Prediction of Cancer Incidence and Mortality in Korea, 2019
Kyu Won JUNG ; Young Joo WON ; Hyun Joo KONG ; Eun Sook LEE
Cancer Research and Treatment 2019;51(2):431-437
PURPOSE: This study aimed to report on cancer incidence and mortality for the year 2019 to estimate Korea's current cancer burden. MATERIALS AND METHODS: Cancer incidence data from 1999 to 2016 were obtained from the Korea National Cancer Incidence Database, and cancer mortality data from 1993 to 2017 were acquired from Statistics Korea. Cancer incidence and mortality were projected by fitting a linear regression model to observed age-specific cancer rates against observed years, then multiplying the projected age-specific rates by the age-specific population. The Joinpoint regression model was used to determine at which year the linear trend changed significantly; we used only the data of the latest trend. RESULTS: A total of 221,347 new cancer cases and 82,344 cancer deaths are expected to occur in Korea in 2019. The most common cancer sites thus far have been the lung, followed by the stomach, colon and rectum, breast, and liver. These five cancers represent half of the overall burden of cancer in Korea. For cancer associated mortality, the most common sites were lung, followed by the liver, colon and rectum, stomach, and pancreas. CONCLUSION: The incidence rate of all cancer in Korea is estimated to decrease gradually. These up-todate estimates of the cancer burden in Korea could be an important resource for planning and evaluating cancer-control programs.
Breast
;
Colon
;
Forecasting
;
Incidence
;
Korea
;
Linear Models
;
Liver
;
Lung
;
Mortality
;
Pancreas
;
Rectum
;
Stomach
9.Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2016
Kyu Won JUNG ; Young Joo WON ; Hyun Joo KONG ; Eun Sook LEE ;
Cancer Research and Treatment 2019;51(2):417-430
PURPOSE: This study presents the 2016 nationwide cancer statistics in Korea, including cancer incidence, survival, prevalence, and mortality. MATERIALS AND METHODS: Cancer incidence data from 1999 to 2016 were obtained from the Korea National Cancer Incidence Database and followed until December 31, 2017. Mortality data from 1983 to 2016 were obtained from Statistics Korea. The prevalence was defined as the number of cancer patients alive on January 1, 2017 among all cancer patients diagnosed since 1999. Crude and age-standardized rates (ASRs) for incidence, mortality, and prevalence and 5-year relative survivals were also calculated. RESULTS: Overall, 229,180 and 78,194 Koreans were newly diagnosed and died from cancer in 2016, respectively. The ASRs for cancer incidence and mortality in 2016 were 269.0 and 79.8 per 100,000 individuals, respectively. The all-cancer incidence rate increased significantly by 3.6% annually from 1999 to 2011 and started to decrease after 2011 (2011-2016; annual percent change, –3.1%). However, overall cancer mortality has decreased 2.7% annually since 2002. The 5-year relative survival rate for patients diagnosed with cancer between 2012 and 2016 was 70.6%, an improvement from the 41.2% for patients diagnosed between 1993 and 1995. CONCLUSION: The cancer prevalence in Korea has increased very fast as survival has improved remarkably. The high prevalence of cancer emphasizes the need for comprehensive cancer control efforts in Korea.
Humans
;
Incidence
;
Korea
;
Mortality
;
Prevalence
;
Survival Rate
10.Psychosocial Health of Disease-Free Breast Cancer Survivors Compared with Matched Non-cancer Controls.
Boyoung PARK ; Moo Hyun LEE ; Sun Young KONG ; Eun Sook LEE
Cancer Research and Treatment 2019;51(1):178-186
PURPOSE: The present study investigated the psychosocial health of disease-free breast cancer survivors who receive health examinations compared to matched non-cancer controls in a community setting. MATERIALS AND METHODS: We used baseline data from the Health Examinee cohort, which is composed of subjects participating in health. The disease-free breast cancer survivors were defined as those who were ≥ 2 years from initial diagnosis of breast cancer who had completed treatment. Females without a history of cancer were randomly selected at 1:4 ratio by 5-year age groups, education, and household income as a comparison group. We analyzed results from the Psychosocial Well-being Index-Short Form (PWI-SF) as a psychosocial health measurement. RESULTS: A total of 347 survivors of breast cancer and 1,388 matched controls were included. Total scores on the PWI-SF were lower in breast cancer survivors than matched non-cancer controls (p=0.006), suggesting a lower level of psychosocial stress in breast cancer survivors. In comparison to the control group, prevalence of drinking, smoking and obesity were lower, while exercising for ≥ 150 min/wk was higher in breast cancer survivors (p < 0.05). These findings suggest that breast cancer survivors have better health behaviors than their noncancer controls. After adjusting for other sociodemographic variables, breast cancer survivors were 36% less likely to be included in the stress group (odds ratio, 0.64; 95% confidence interval, 0.42 to 0.98). CONCLUSION: The disease-free breast cancer survivors resuming daily life demonstrated better psychosocial health status compared to matched non-cancer controls.
Breast Neoplasms*
;
Breast*
;
Cohort Studies
;
Diagnosis
;
Drinking
;
Education
;
Family Characteristics
;
Female
;
Health Behavior
;
Humans
;
Obesity
;
Prevalence
;
Smoke
;
Smoking
;
Survivors*

Result Analysis
Print
Save
E-mail